Evidence map›Paper›PMID 33293516›Full record

ArticleNature communications2020

Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.

Mei Song, Oladapo O Yeku, Sarwish Rafiq, Terence Purdon, Xue Dong, Lijing Zhu, Tuo Zhang, Huan Wang, Ziqi Yu, Junhua Mai and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 3 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 3 syntheses or guidelines pooled it, 165 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Identification of novel molecular subtypes in ovarian cancerThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Hypoxia-driven remodeling of SELENOPNature communications · 2026
    Article

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Mei SongDepartment of Microbiology and Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065, USA.
Oladapo O YekuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Sarwish RafiqDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID 0000-0002-9295-3065
Terence PurdonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Xue DongDepartment of Microbiology and Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065, USA.
Lijing ZhuThe Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, 210008, Nanjing, China.
Tuo ZhangDepartment of Microbiology and Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065, USA.ORCID 0000-0001-5396-918X
Huan WangSheng Yushou Center of Cell Biology and Immunology, School of Life Science and Biotechnology, Shanghai Jiao Tong University, 200240, Shanghai, China.
Ziqi YuDepartment of Microbiology and Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065, USA.
Junhua MaiDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.ORCID 0000-0001-8374-4352
Haifa ShenDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Briana NixonImmunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA.
Ming LiImmunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA.ORCID 0000-0002-1383-0535
Renier J BrentjensDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID 0000-0002-3364-5388
Xiaojing MaDepartment of Microbiology and Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065, USA. xim2002@med.cornell.edu.ORCID 0000-0003-3043-1840
Memorial Sloan Kettering Cancer Center · USCornell University · USHouston Methodist · USShanghai Jiao Tong University · CNNanjing Drum Tower Hospital · CN

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Personalized Immunotherapy of Patients with Ovarian CancerP01CA190174 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SABBATINI, PAUL J, SPRIGGS, DAVID R · 2015 to 2019
$10.5M
Mechanism of Intratumoral Transport of Particulate DrugsR01CA222959 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, SHU-HSIA, LIU, XUEWU · 2018 to 2023
$2.3M
Tumor vasculature-targeted nanotherapeutics for DNA damage responseR01CA193880 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$1.8M
Investigation of EDD's extraordinary tumorigenic activitiesR03CA230573 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MA, XIAOJING · 2018 to 2019
$170k
NCI NIH HHS P01 CA190174NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA193880NCI NIH HHS R01 CA222959NCI NIH HHS R03 CA230573
6 · The paper itself

Abstract

Immunosuppressive tumor microenvironment (TME) and ascites-derived spheroids in ovarian cancer (OC) facilitate tumor growth and progression, and also pose major obstacles for cancer therapy. The molecular pathways involved in the OC-TME interactions, how the crosstalk impinges on OC aggression and chemoresistance are not well-characterized. Here, we demonstrate that tumor-derived UBR5, an E3 ligase overexpressed in human OC associated with poor prognosis, is essential for OC progression principally by promoting tumor-associated macrophage recruitment and activation via key chemokines and cytokines. UBR5 is also required to sustain cell-intrinsic β-catenin-mediated signaling to promote cellular adhesion/colonization and organoid formation by controlling the p53 protein level. OC-specific targeting of UBR5 strongly augments the survival benefit of conventional chemotherapy and immunotherapies. This work provides mechanistic insights into the novel oncogene-like functions of UBR5 in regulating the OC-TME crosstalk and suggests that UBR5 is a potential therapeutic target in OC treatment for modulating the TME and cancer stemness.

Indexed as

AdultAgedAnimalsAscitesCarcinoma, Ovarian EpithelialCell Line, TumorDisease Models, AnimalDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsImmunotherapy, AdoptiveMacrophages, PeritonealMiceMice, KnockoutImmune Checkpoint InhibitorsReceptors, Chimeric AntigenUbiquitin-Protein LigasesUBR5 protein, humanUBR5 protein, mouse

Identifiers

PMID33293516
PMCPMC7722725
OpenAlexW3112394757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.